Atlas Trials

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Clinical trial NCT02950220 · COMPLETED

Trial details

NCT number
NCT02950220
Sponsor
Kami Maddocks
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaMediastinal LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma
Start date
2017-01-12
Primary completion
2018-11-19
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.